ICE Pharma to Showcase Bile Acid Expertise at CPHI Frankfurt 2025

Published on: October 15, 2025

Conference | CPHI Europe

The company will also highlight its sustainability strategies and quality solutions at the event.

ICE Pharma, a producer of bile acid-derived APIs, excipients, and finished dosage forms, announced on Oct. 15, 2025, that it will showcase its innovations and sustainability strategies at Booth 9.1 A94 at CPHI Frankfurt 2025, which is being held from Oct. 28–30. Highlights include the company’s ursodeoxycholic acid (UDCA) production and bile acid derivatives (1).

ICE’s products assist in the therapeutical applications for liver, metabolic, and neurological diseases and are developed in the company’s five R&D centers. The company also has a quality framework for ensuring traceability, viral inactivation, closed manufacturing systems, and regulatory compliance.

How is ICE Pharma meeting sustainability goals?

ICE Pharma will be presenting its four-pillar strategy for sustainability: Fighting Illness through Product Innovation, Caring for People, Accelerating Sustainable Operations, and Building Strong Relationships. The company is using this strategy to make decisions across resource management, waste reduction, energy sourcing, and stakeholder engagement. Following its reduce, reuse, recycle philosophy, ICE will be presenting an eco-designed booth at CPHI Frankfurt that has been built from recyclable materials from past events, minimizing environmental impact.

“At ICE Pharma, quality and environmental responsibility are inseparable,” said Agostino Barazza, Chief Executive Officer. “By mastering bile acids with rigorous controls and sustainable design, we are delivering medicines with impact and integrity.”

“Our sustainability roadmap strengthens operations and inspires confidence across our supply chain, empowering partners to deliver therapies benefiting from bile acid science,” added Roger Viney, Chief Commercial Officer.

What else is ICE Pharma showcasing at the event?

ICE will be celebrating the centennial of ABC Farmaceutici at CPHI Frankfurt, which was founded in 1925 in Turin and acquired by ICE in 2021 (2). ABC Farmaceutici will highlight its achievements and its research concentrations at the event. A special “100 Years” logo will also be unveiled at the conference.

“Reaching 100 years is not only a celebration of our past, but also a promise to the future,” said Severino Previtali, ABC Farmaceutici Business Unit director, in the press release (3). “This milestone reminds us of the generations of people who have contributed to our success, and it inspires us to continue driving innovation, building strong collaborations, and making a meaningful impact on global health.”

What is ICE Pharma’s approach to quality?

As part of its coverage of DCAT, PharmTech spoke with Roger Viney, chief commercial officer of ICE Pharma, aboutquality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry (4). In the interview, Viney talked about how regulatory harmonization is critical and increases the security of the supply chain. He also talked about the importance of traceability and knowing the origin of animal-derived material. The interview can be viewed here.

References

ICE Pharma. ICE Pharma Highlights Sustainability and Bile Acid Expertise at CPhI Worldwide 2025. Press Release. Oct. 15, 2025.
Lavery, P. ABC Farmaceutici to Mark 100th Anniversary with CPHI Frankfurt Display. PharmTech.com. Sept. 18, 2025. https://www.pharmtech.com/view/abc-farmaceutici-mark-100th-anniversary-cphi-frankfurt-display
ICE Pharma. ABC Farmaceutici Celebrates 100 Years of Pharmaceutical Excellence and Innovation. Press Release. Sept. 17, 2025.
Thomas, F. DCAT Week 2025: Quality and Compliance for Animal-derived Products. PharmTech.com. March 18, 2025.